BIOTON S.A. (BIO.WA)
PLN 2.98
(-0.83%)
PLN 2.98
(-0.83%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 68.69 Million PLN | -10.08% |
| 2022 | 76.39 Million PLN | -30.6% |
| 2021 | 110.07 Million PLN | -0.02% |
| 2020 | 110.1 Million PLN | -13.6% |
| 2019 | 127.42 Million PLN | 14.19% |
| 2018 | 111.59 Million PLN | -43.7% |
| 2017 | 198.22 Million PLN | -13.53% |
| 2016 | 229.24 Million PLN | 1.31% |
| 2015 | 226.27 Million PLN | 12.41% |
| 2014 | 201.29 Million PLN | -11.18% |
| 2013 | 226.63 Million PLN | 0.02% |
| 2012 | 226.58 Million PLN | -14.03% |
| 2011 | 263.55 Million PLN | 44.96% |
| 2010 | 181.81 Million PLN | -28.09% |
| 2009 | 252.83 Million PLN | -48.69% |
| 2008 | 492.7 Million PLN | 20.19% |
| 2007 | 409.92 Million PLN | 561.68% |
| 2006 | 61.95 Million PLN | 43.51% |
| 2005 | 43.17 Million PLN | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 56.62 Million PLN | -8.47% |
| 2024 Q1 | 61.86 Million PLN | -9.94% |
| 2023 FY | 68.69 Million PLN | -10.08% |
| 2023 Q1 | 75.46 Million PLN | -1.21% |
| 2023 Q3 | 75.09 Million PLN | -2.15% |
| 2023 Q2 | 76.74 Million PLN | 1.69% |
| 2023 Q4 | 68.69 Million PLN | -8.53% |
| 2022 Q2 | 90.63 Million PLN | -5.12% |
| 2022 Q1 | 95.53 Million PLN | -13.21% |
| 2022 FY | 76.39 Million PLN | -30.6% |
| 2022 Q4 | 76.39 Million PLN | -12.13% |
| 2022 Q3 | 86.94 Million PLN | -4.08% |
| 2021 FY | 110.07 Million PLN | -0.02% |
| 2021 Q2 | 111.88 Million PLN | 7.22% |
| 2021 Q1 | 104.34 Million PLN | -5.23% |
| 2021 Q3 | 118.8 Million PLN | 6.19% |
| 2021 Q4 | 110.07 Million PLN | -7.35% |
| 2020 FY | 110.1 Million PLN | -13.6% |
| 2020 Q2 | 109.09 Million PLN | -16.42% |
| 2020 Q3 | 106.44 Million PLN | -2.43% |
| 2020 Q4 | 110.1 Million PLN | 3.44% |
| 2020 Q1 | 130.52 Million PLN | 2.43% |
| 2019 FY | 127.42 Million PLN | 14.19% |
| 2019 Q1 | 138.04 Million PLN | 23.7% |
| 2019 Q2 | 146.18 Million PLN | 5.9% |
| 2019 Q3 | 134.84 Million PLN | -7.76% |
| 2019 Q4 | 127.42 Million PLN | -5.5% |
| 2018 FY | 111.59 Million PLN | -43.7% |
| 2018 Q4 | 111.59 Million PLN | -18.21% |
| 2018 Q1 | 184.14 Million PLN | -7.11% |
| 2018 Q2 | 183.03 Million PLN | -0.6% |
| 2018 Q3 | 136.43 Million PLN | -25.46% |
| 2017 Q4 | 198.22 Million PLN | -1.56% |
| 2017 Q2 | 203.41 Million PLN | -0.68% |
| 2017 Q1 | 204.81 Million PLN | -10.66% |
| 2017 FY | 198.22 Million PLN | -13.53% |
| 2017 Q3 | 201.37 Million PLN | -1.0% |
| 2016 Q3 | 214.47 Million PLN | 4.94% |
| 2016 Q1 | 216.03 Million PLN | -4.53% |
| 2016 FY | 229.24 Million PLN | 1.31% |
| 2016 Q2 | 204.37 Million PLN | -5.4% |
| 2016 Q4 | 229.24 Million PLN | 6.88% |
| 2015 Q1 | 189.56 Million PLN | -5.83% |
| 2015 FY | 226.27 Million PLN | 12.41% |
| 2015 Q4 | 226.27 Million PLN | 7.76% |
| 2015 Q3 | 209.98 Million PLN | 3.42% |
| 2015 Q2 | 203.04 Million PLN | 7.11% |
| 2014 Q3 | 207.73 Million PLN | -0.37% |
| 2014 Q4 | 201.29 Million PLN | -3.1% |
| 2014 Q2 | 208.49 Million PLN | -11.35% |
| 2014 FY | 201.29 Million PLN | -11.18% |
| 2014 Q1 | 235.2 Million PLN | 3.78% |
| 2013 Q3 | 234.08 Million PLN | -0.13% |
| 2013 Q4 | 226.63 Million PLN | -3.18% |
| 2013 FY | 226.63 Million PLN | 0.02% |
| 2013 Q1 | 229.49 Million PLN | 1.28% |
| 2013 Q2 | 234.39 Million PLN | 2.14% |
| 2012 Q3 | 254.37 Million PLN | 9.88% |
| 2012 Q1 | 249.51 Million PLN | -5.33% |
| 2012 Q4 | 226.58 Million PLN | -10.92% |
| 2012 FY | 226.58 Million PLN | -14.03% |
| 2012 Q2 | 231.49 Million PLN | -7.22% |
| 2011 Q3 | 228.22 Million PLN | 9.54% |
| 2011 Q4 | 263.55 Million PLN | 15.48% |
| 2011 FY | 263.55 Million PLN | 44.96% |
| 2011 Q1 | 171.9 Million PLN | -5.45% |
| 2011 Q2 | 208.35 Million PLN | 21.2% |
| 2010 Q2 | 115.17 Million PLN | -49.54% |
| 2010 Q1 | 228.26 Million PLN | -9.72% |
| 2010 FY | 181.81 Million PLN | -28.09% |
| 2010 Q4 | 181.81 Million PLN | 1.45% |
| 2010 Q3 | 179.22 Million PLN | 55.61% |
| 2009 Q4 | 252.83 Million PLN | 0.0% |
| 2009 FY | 252.83 Million PLN | -48.69% |
| 2008 FY | 492.7 Million PLN | 20.19% |
| 2007 FY | 409.92 Million PLN | 561.68% |
| 2006 FY | 61.95 Million PLN | 43.51% |
| 2005 FY | 43.17 Million PLN | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioceltix S.A. | 175.05 Thousand PLN | -39140.362% |
| Captor Therapeutics Spolka Akcyjna | 3.77 Million PLN | -1718.237% |
| Mabion S.A. | 35.82 Million PLN | -91.73% |
| Molecure S.A. | 7.13 Million PLN | -862.169% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Pharmena S.A. | 181 Thousand PLN | -37851.934% |
| Poltreg S.A. | 8.19 Million PLN | -738.333% |
| Pure Biologics Spólka Akcyjna | 12.93 Million PLN | -430.94% |
| Ryvu Therapeutics S.A. | 906 Thousand PLN | -7482.009% |
| Synthaverse S.A. | 70.04 Million PLN | 1.926% |
| Urteste S.A. | 627 Thousand PLN | -10855.821% |